x

Search for a clinical trial

* (*) mandatory field

A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC) - UK

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : No
  • Status : Terminated trial
  • Funding body(ies) :
  • Geographic coverage : Global
  • Sponsor : Bayer ag
  • Website
    • Phase : II
  • Principal investigator of clinical trial

  • Dr Paul ROSS
  • Department of Medical Oncology
  • King's College Hospital
  • Denmark Hill
  • LONDON SE5 9RS
  • UNITED KINGDOM
  • More information
  • Phone  : 44 (0)
  • Fax  : -
Last update: June 2017

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.